Literature DB >> 26351383

Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease.

F Goutorbe1, M Goutte2, R Minet-Quinard3, A-L Boucher1, B Pereira4, G Bommelaer2, A Buisson5.   

Abstract

BACKGROUND AND AIMS: Fecal calprotectin [fcal] is a biomarker of Crohn's disease [CD] endoscopic activity. Identifying the endoscopic situations in which fcal is less reliable remains unexplored. We aimed to determine the endoscopic factors influencing fcal level in CD.
METHODS: Overall, 53 CD patients consecutively and prospectively underwent colonoscopy, with CD Endoscopic Index of Severity [CDEIS] calculation and stool collection. Fcal was measured using a quantitative immunochromatographic test. Correlation analysis was done with Pearson statistics.
RESULTS: Fcal was correlated with CDEIS [0.66, p < 0.001]. In univariate analysis, fcal was correlated with the affected surface [0.65, p < 0.001] and the ulcerated surface [0.47, p < 0.001]. Fcal was significantly associated with ulceration depth, with median fcal of 867.5 µg/g, 1251.0 µg/g, and 1800.0 µg/g, in patients presenting with non-ulcerated lesions, superficial ulcerations [SU], and deep ulcerations [DU], respectively. Lesion locations did not influence fcal. In multivariate analysis, fcal was associated with affected surface [p = 0.04] and the presence of CD lesions. Moreover, fcal increased with the ulceration depth [p = 0.03]. However, ulcerated surface and CD location did not affect fcal. Using a receiver operating characteristic [ROC] curve, we showed that fcal of 400 µg/g was the best compromise between sensitivity [0.76] and specificity [0.77], whereas fcal ≥ 200 µg/g was highly sensitive [0.86] to detect SU or DU.
CONCLUSIONS: Fcal is a very reliable biomarker to detect endoscopic ulcerations in CD. We suggest repeating measurement in case of intermediary results [200-400 µg/g] in daily practice. Fcal level is mostly influenced by the presence of CD lesions [even non-ulcerated], in a depth-related manner and by the affected surface.
Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’ s disease; Crohn’s Disease Endoscopic Index of Severity; biomarker; endoscopy; fecal calprotectin

Mesh:

Substances:

Year:  2015        PMID: 26351383     DOI: 10.1093/ecco-jcc/jjv150

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  14 in total

1.  Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.

Authors:  Anthony Buisson; Wing Yan Mak; Michael J Andersen; Donald Lei; Stacy A Kahn; Joel Pekow; Russel D Cohen; Nada Zmeter; Bruno Pereira; David T Rubin
Journal:  J Crohns Colitis       Date:  2019-08-14       Impact factor: 9.071

Review 2.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

3.  Serum platelet factor 4 is a reliable activity parameter in adult patients with inflammatory bowel disease: A pilot study.

Authors:  Lei Ye; Yu-Ping Zhang; Na Yu; Ya-Xu Jia; Shu-Jun Wan; Fang-Yu Wang
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

4.  Faecal calprotectin and magnetic resonance imaging in detecting Crohn's disease endoscopic postoperative recurrence.

Authors:  Pierre Baillet; Guillaume Cadiot; Marion Goutte; Felix Goutorbe; Hedia Brixi; Christine Hoeffel; Christophe Allimant; Maud Reymond; Hélène Obritin-Guilhen; Benoit Magnin; Gilles Bommelaer; Bruno Pereira; Constance Hordonneau; Anthony Buisson
Journal:  World J Gastroenterol       Date:  2018-02-07       Impact factor: 5.742

5.  Diagnostic accuracy of faecal calprotectin in patients with active perianal fistulas.

Authors:  Toer W Stevens; Geert R D'Haens; Marjolijn Duijvestein; Willem A Bemelman; Christianne J Buskens; Krisztina B Gecse
Journal:  United European Gastroenterol J       Date:  2019-02-24       Impact factor: 4.623

6.  Serum Free Thiols Are Superior to Fecal Calprotectin in Reflecting Endoscopic Disease Activity in Inflammatory Bowel Disease.

Authors:  Arno R Bourgonje; Ruben Y Gabriëls; Martin H de Borst; Marian L C Bulthuis; Klaas Nico Faber; Harry van Goor; Gerard Dijkstra
Journal:  Antioxidants (Basel)       Date:  2019-09-01

7.  Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease.

Authors:  Nicholas A Kennedy; Gareth-Rhys Jones; Nikolas Plevris; Rebecca Patenden; Ian D Arnott; Charlie W Lees
Journal:  Clin Gastroenterol Hepatol       Date:  2019-02-14       Impact factor: 11.382

8.  Treatment of Active Crohn's Disease with Exclusive and Partial Enteral Nutrition: A Pilot Study in Adults.

Authors:  Catherine L Wall; Richard B Gearry; Andrew S Day
Journal:  Inflamm Intest Dis       Date:  2018-06-26

9.  Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease?: a systematic review.

Authors:  Ebby George Simon; Richard Wardle; Aye Aye Thi; Jeanette Eldridge; Sunil Samuel; Gordon William Moran
Journal:  Intest Res       Date:  2019-02-07

10.  Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location.

Authors:  Anthony Buisson; Wing Yan Mak; Michael J Andersen; Donald Lei; Joel Pekow; Russell D Cohen; Stacy A Kahn; Bruno Pereira; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2021-06-15       Impact factor: 7.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.